Connect with us

Press Release

Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals

Published

on

Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals

Business Wire India− JR-141 is a potentially transformative therapy designed to deliver proteins to the brain and peripheral tissues to treat neuronopathic features along with somatic symptoms of Hunter syndrome via intravenous administration

− Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval

− Takeda receives a separate option to obtain an exclusive license to commercialize in the U.S. after completion of the global Phase 3 program
 

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and JCR Pharmaceuticals Co., Ltd. (TSE:4552) (“JCR”) announced today a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II). Hunter syndrome is caused by a deficiency of IDS and manifests in different forms. JR-141, applied with J-Brain Cargo®, JCR’s proprietary blood-brain barrier (BBB) technology, is engineered to transport the therapeutic enzyme across the BBB to directly reach the brain and address both the somatic and neuronopathic manifestations of the disease, which can lead to progressive cognitive decline.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005353/en/

 

Under the terms of the exclusive collaboration and license agreement, Takeda will exclusively commercialize JR-141 outside of the United States, including Canada, Europe, and other regions (excluding Japan and certain other Asia-Pacific countries). JCR will receive an upfront payment for such ex-U.S. license, and is eligible to receive additional development and commercial milestones as well as tiered royalties on potential sales. The two companies will collaborate to bring this therapy to patients as quickly as possible upon completion of the global Phase 3 program, which will be conducted by JCR.

 

Takeda receives an option under a separate option agreement, which allows Takeda to acquire an exclusive license to commercialize JR-141 in the U.S. upon completion of the Phase 3 program.

 

“Takeda is committed to continuously improving the way Hunter syndrome is treated. JR-141 introduces a new way to deliver proteins across the blood-brain barrier, overcoming our current challenges to treat the underlying neuronopathic manifestations of Hunter syndrome and help maintain or improve cognitive function in these patients,” said Dan Curran, M.D., Head, Rare Genetics & Hematology Therapeutic Area Unit at Takeda. “We will work closely with JCR to apply our expertise in enzyme replacement therapies with the hope of bringing this potentially transformative therapy to patients as quickly as possible.”

 

“JCR is pleased to have reached an agreement with Takeda who is well placed to achieve our common goal of maximizing the impact of JR-141,” said Shin Ashida, President, Chairman of JCR. “Our mission is to provide transformative treatment options as soon as possible to patients with lysosomal storage disorders (LSDs) with central nervous system symptoms, such as Hunter syndrome. JR-141 is the first-ever approved biopharmaceutical in Japan that penetrates the blood-brain barrier. I expect that we will be able to achieve this mission through our partnership with Takeda to deliver a new treatment option to Hunter patients around the world as swiftly as possible.”

 

JR-141 met its primary endpoint in an open-label Phase 2/3 clinical trial in Japan demonstrating significant reductions in heparan sulfate (HS) in the cerebrospinal fluid, a biomarker for assessing the drug’s effectiveness in reducing disease-causing substrate in the central nervous system, in all subjects for whom measurements were available after 52 weeks of treatment. Somatic disease control was maintained in patients who switched from standard enzyme replacement therapy (ERT). The study also demonstrated an improvement in somatic symptoms in participants who had not previously received standard ERT prior to the start of the trial. Additionally, a neurocognitive development assessment demonstrated maintenance or improvement of age-equivalent function in 21 of the 25 patients at one year. There were no reports of serious treatment-related adverse events in the trial.1

 

About JR-141

 

JR-141 is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in subjects with Hunter syndrome. It is expected to be effective against the neuronopathic manifestations of the disease by crossing the BBB through transferrin receptor mediated transcytosis using J-Brain Cargo®, JCR’s proprietary BBB technology. Uptake into cells is mediated through the transferrin receptor and mannose-6-phosphate receptor. JCR has advanced development activities by establishing the necessary evidence from the molecular design stage to the nonclinical and clinical trial phases. In non-clinical trials, JCR has confirmed both high affinity binding of JR-141 to transferrin receptors, and passage across the BBB into neuronal cells as evidenced by electron microscopy.

 

In addition, JCR has confirmed that using J-Brain Cargo® technology, enzymes are taken up into various brain tissues. A decrease in substrate accumulation has also been confirmed in an animal model of Hunter syndrome.2,3,4 In several clinical trials with JR-141, JCR obtained evidence of reduction of heparan sulfate concentrations in the CSF, a biomarker for assessing the drug’s effectiveness in reducing disease-causing substrate in the central nervous system, consistent with the results obtained from non-clinical studies. JCR also obtained clinical results that demonstrate positive effects of JR-141 on neurocognition.5,6,7,8

 

JR-141 was approved by the Ministry of Health, Labour and Welfare and marketed since May 2021 under the brand name “IZCARGO® I.V. Infusion 10mg.”

 

About Hunter Syndrome

 

Hunter syndrome is a severely debilitating, rare lysosomal disease caused by a deficiency of iduronate-2-sulfatase, an enzyme that is needed to break down substances in the body called glycosaminoglycans (GAGs).9 Without this enzyme, GAGs can build up, causing a range of disease-related signs and symptoms.9,10 Roughly two of every three patients with Hunter syndrome are also affected with progressive cognitive decline.11 Hunter syndrome affects 1 in 162,000 total live births, and almost exclusively males.12

 

About Takeda Pharmaceutical Company Limited

 

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

 

About JCR Pharmaceuticals Co., Ltd.

 

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 46-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

 

Important Notice From Takeda

 

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

 

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

 

Forward-Looking Statements

 

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

JCR Pharmaceuticals Cautionary Statement Regarding Forward-Looking Statements

 

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

 

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

 

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

 

1. Okuyama T, Eto Y, Sakai N, et al. A phase 2/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Molecular Therapy. 2021;29(2):671-679.
2. Sonoda, et al. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. Mol Ther. 2018; 26(5): 1366-74.
3. Morimoto, et al. Clearance of heparin sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol. Ther. 2021; https://doi.org/10.1016/j.ymthe.2021.01.027.
4. Yamamoto et al. Nonclinical Safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II. Mol Genet Metab Rep. 2021; https://doi.org/10.1016/j.ymgmr.2021.100758.
5. Okuyama, et al. Iduronate-2-sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Mol Ther. 2020; 27(2): 456-464.
6. Okuyama, et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther. 2020; 29(2): 671-679.
7. Giugliani, et al. Iduronate-2-sulfatase fused with anti-human transferrin receptor antibody, pabinafusp alfa, for treatment of neuronopathic and non-neuronopathic mucopolysaccharidosis II: Report of a phase 2 trial in Brazil. Mol Ther. 2021; https://doi.org/10.1016/j.ymthe.2021.03.019.
8. Giugliani, et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II; an Integrated Analysis of Preclinical and Clinical Data. Preprints 2021; 2021090192.
9. Wraith JE, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008; 167(3):267-77.
10. Martin R. Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome). PEDIATRICS. Volume 121, Number 2, February 2008.
11. Young I. A clinical and genetic study of Hunter’s syndrome. 2 Differences between the mild and severe forms.
12. Meikle PJ, et al. Prevalence of Lysosomal Storage Disorders. JAMA. 1999; 281(3):249-54.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005353/en/

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Press Release

Orbital Insight Integrates with Esri’s ArcGIS Platform to Streamline Satellite and Sensor Imagery Analysis

Published

on

By

Orbital Insight Integrates with Esri’s ArcGIS Platform to Streamline Satellite and Sensor Imagery Analysis

Business Wire India

Orbital Insight’s fusion of multisensor geospatial data and state-of-the-art algorithms has been helping customers address critical concerns for years—from determining the flow of container ship traffic amid unprecedented supply chain delays to visualizing dynamic intelligence and defense-related threats and anomalies across the globe. With the adoption of Esri’s ArcGIS Platform, Orbital Insight is making it easier for its users to integrate with ArcGIS and analyze their data.

 

Customers of Esri, the world leader in location intelligence, who also use Orbital Insight GO can now seamlessly work between both systems, making it easier to meet spatial challenges with Esri basemap visualizations directly within the Orbital Insight GO platform and export their analysis to ArcGIS.

 

The integration with Esri’s ArcGIS Platform provides an integral reference point for analysts as well as a more cohesive and natural user experience. More collaboration is planned, including eventually incorporating Esri’s geocoding technology into Orbital Insight GO.

 

“We are proud to share with Orbital Insight the common goal of helping people make important decisions on a worldwide scale by taking a geographic approach,” said Jack Dangermond, Esri founder and president. “It only makes sense to make that process easier so our users can focus on what they do best.”

 

Orbital Insight, founded in 2013, uses artificial intelligence (AI) to synthesize multiple sources of geospatial data—including satellite images, mobile location, connected cars, and Internet of Things (IoT) devices—into a unified platform that can identify objects; detect anomalies; and observe changes in land use, infrastructure, and human activities across the globe.

 

Orbital Insight executives recently demonstrated the new streamlined user experience at the US Geospatial Intelligence Foundation’s annual GEOINT Symposium for industry professionals, showing the ease of importing and exporting data between Orbital Insight GO and ArcGIS.

 

“Making that seamless was a really big hit,” said Jens Tellefsen, senior vice president of product and design for Orbital Insight. GO is currently being deployed in top security military networks that have long used Esri software. Companies across commercial sectors, particularly real estate, financial services, mining, and consumer packaged goods, are also using GO to monitor changes globally.

 

“We serve similar and overlapping sets of end users, and our analysis is often combined and visualized in the ArcGIS system,” continued Tellefsen. “With our partnership, we have added ArcGIS basemaps in our application to provide a consistent user experience between Orbital Insight GO and ArcGIS. With our native ArcGIS data support, users can now easily add our analysis directly into ArcGIS with a few simple clicks, resulting in significant productivity improvement for geospatial analysts.”

 

The increasing customer overlap between the two companies was a primary driver for Orbital Insight to adopt ArcGIS Platform.

 

Learn more about how ArcGIS Platform can help users in all industries integrate location intelligence in their applications.

 

About Orbital Insight

 

Orbital Insight is the geospatial software and analytics company that helps organizations understand what’s happening on and to the Earth. Customers including Unilever, Airbus, RBC Capital Markets, The World Bank, and the U.S. Department of Defense use Orbital Insight’s self-service analytics platform to make smarter business decisions, build sustainable supply chains, and improve national security. For more information, visit www.orbitalinsight.com.

 

About Esri

 

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.

 

Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005090/en/

Continue Reading

Press Release

ElegantJ BI Embedded BI Solution Is Named as a Representative Vendor in Gartner 2021 ‘Market Guide for Embedded Analytics’, Published October, 2021

Published

on

By

ElegantJ BI Embedded BI Solution Is Named as a Representative Vendor in Gartner 2021 ‘Market Guide for Embedded Analytics’, Published October, 2021

Business Wire India

Elegant MicroWeb is pleased to announce that its ElegantJ BI Embedded BI solution has been included as a Representative Vendor in the Gartner Market Guide for Embedded Analytics, published October 4, 2021 (ID G00748546).

CEO, Kartik Patel says, “We are proud to be recognized and included in the October 2021 Gartner Market Guide for Embedded Analytics. We feel that this recognition validates our team effort to continuously improve and upgrade our Business Intelligence and Augmented Analytics tools and solution and to provide cutting-edge technology in an intuitive interface designed for business users to support Citizen Data Scientist initiatives and data democratization.”
 
The ElegantJ BI Embedded BI tool is an easy-to-use tool designed to support business users and their use of embedded analytics within familiar enterprise applications, and to enable access to analytics and crucial, timely data for public websites and mobile applications.
 
“Our embedded BI tool is part of our Smarten Augmented Analytics solution, and is powered by the ElegantJ BI product,” says Patel. “The Embedded BI approach is designed to improve user adoption, lower TCO and improve ROI, and its integration APIs provide intuitive, self-serve BI tools from within enterprise applications to put the power of facts, data and business insight in the hands of business users.”
 
The ElegantJ BI Smarten Embedded BI solution is a crucial part of the Smarten augmented analytics suite and includes smart data visualization, assisted predictive modeling, natural language processing (NLP) and search analytics, with machine learning and many other sophisticated features.
 
Read more in the Gartner report: 2021 Market Guide for Embedded BI, published 2021, October, (Gartner Subscription Required)
Source: Gartner, Market Guide for Embedded Analytics, James Richardson, Julian Sun, Kevin Quinn, 4 October 2021
 
Disclaimer: Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization, and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Continue Reading

Press Release

Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure

Published

on

By

Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure

Business Wire India

Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced the winners of the 2021 Going Digital Awards in Infrastructure. The annual awards program recognizes the extraordinary work of Bentley software users advancing infrastructure design, construction, and operations throughout the world.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005219/en/

 

Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure (Photo: Business Wire)

Sixteen independent jury panels selected the 57 finalists from nearly 300 nominations submitted by more than 230 organizations from 45 countries encompassing 19 categories. To see the Going Digital Awards in Infrastructure finalists present their projects, click here.

 

Bentley Systems showcased 19 Going Digital Awards in Infrastructure winners on December 2 during the 2021 Year in Infrastructure and Going Digital Awards virtual event. On the previous day at the virtual event, 22 Founders’ Honorees were recognized, representing organizations or individuals whose undertakings contribute notably to infrastructure advancement and/or environmental/social development goals.

 

The winners of the 2021 Going Digital Awards in Infrastructure are:

 

Bridges
New York State Department of Transportation
East 138th Street over the Major Deegan Expressway
New York City, New York, United States

 

Buildings and Campuses
Volgogradnefteproekt, LLC
High-tech Multifunctional Medical Complex
Yukki, St. Petersburg, Russia

 

Digital Cities
Hubei International Logistics Airport Co., Ltd., Shenzhen S.F. Taisen Holdings (Group) Co., Ltd., Airport Construction Engineering Co., Ltd.
Ezhou Huahu Airport Project
Ezhou, Hubei, China

 

Digital Construction
Clark Construction Group, LLC
SeaTac Airport International Arrivals Facility
Seattle, Washington, United States

 

Geotechnical Engineering
China Water Resources Beifang Investigation, Design and Research Co. Ltd.
Geological Survey of Water Conservancy and Hydropower Engineering
Tibet, China

 

Land and Site Development
Liaoning Water Conservancy and Hydropower Survey and Design Research Institute Co., Ltd.
Dongtaizi Reservoir Project
Chifeng, Inner Mongolia, China

 

Manufacturing
WISDRI Engineering & Research Incorporation Limited
Converter-based Continuous Casting Project of Jinnan Steel Phase II Quwo Base Capacity Reduction and Replacement Project
Quwo, Shanxi, China

 

Mining and Offshore Engineering
Polyus
Construction of the Blagodatnoye Mill-5
Krasnoyarsk, Krasnoyarsk Krai, Russia

 

Power Generation
Capital Engineering and Research Incorporation Ltd.
The World’s First 60MW Subcritical Blast Furnace Gas Power Generation Project
Changshu, Jiangsu, China

 

Project Delivery Information Management
Mott MacDonald Systra JV with Balfour Beatty Vinci
HS2 Phase 1 Main Civil Construction Works
London, United Kingdom

 

Rail and Transit
Network Rail + Jacobs
Transpennine Route Upgrade
Manchester/Leeds/York, United Kingdom

 

Reality Modeling
HDR
Diablo Dam Digital Twin Modeling
Whatcom County, Washington, United States

 

Road and Rail Asset Performance
Collins Engineers, Inc.
Stone Arch Bridge Rehabilitation
Minneapolis, Minnesota, United States

 

Roads and Highways
PT Hutama Karya (Persero)
Trans Sumatera Toll Road Project Section Serbelawan-Pematangsiantar
Pematangsiantar, Sumatera Utara, Indonesia

 

Structural Engineering
HDR and the PennFIRST Team
The Pavilion at Penn Medicine
Philadelphia, Pennsylvania, United States

 

Utilities and Communications
PowerChina Hubei Electric Engineering Co., Ltd.
Suixian and Guangshui 80MWp Ground-based Photovoltaic Power Project of Hubei Energy Group
Guangshui, Hubei, China

 

Utilities and Industrial Asset Performance
Canadian Energy Company
Asset Data Lifecycle Program
Fort McMurray, Alberta, Canada

 

Water and Wastewater Treatment Plants
Larson & Toubro Construction
Khatan Group of Villages Water Supply Scheme (Surface Water Treatment), UP, India
Khatan, Uttar Pradesh, India

 

Water, Wastewater and Stormwater Networks
Companhia Águas de Joinville (CAJ)
Contingency Plan to Ensure Supply in the Event of Drought (Joinville-Santa Catarina)
Joinville, Santa Catarina, Brazil

 

The students winning the Future Infrastructure Star Challenge are:

 

Judge’s Choice Winner
Elif Gungormus Deliismail
Mini-Modular-Plant for Digitized Sustainable Campus
Izmir Institute of Technology, Turkey

 

People’s Choice Winner
Rodman Raul Cordova Rodriguez
Innovative Dam and Hydroelectric Project
Pontifical Catholic University of Rio de Janeiro, Brazil

 

To view the project descriptions and access the images, visit the Going Digital Awards in Infrastructure webpage. Detailed descriptions of all nominated projects will be published in the print and digital versions of Bentley’s 2021 Infrastructure Yearbook in early 2022. To review the past editions of this publication, access Bentley’s Infrastructure Yearbooks.

 

Watch the executive sessions and the Going Digital Awards finalists’ presentations from the 2021 Year in Infrastructure and Going Digital Awards virtual event on-demand here.

 

# #

 

About Bentley Systems
Bentley Systems (Nasdaq:BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.

 

www.bentley.com

 

© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, iTwin, MicroStation, ProjectWise, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005219/en/

Continue Reading

Trending